BIO.B
Bio-Rad Laboratories, Inc. Class B · NYSE
- Sector Health Technology
- Industry Medical Specialties
- Website -
- Employees(FY) -
- ISIN US0905721082
Performance
-1.31%
1W
-17.53%
1M
-23.72%
3M
-20.49%
6M
-22.04%
YTD
-22.86%
1Y
Profile
-
Technical Analysis of BIO.B 2025-03-13
Technical Scores and Rating
Moving Average Score
Oscillator Score
Technical Rating
Recent News & Updates
- 2025-02-17 09:45
- 2025-02-15 10:05
- 2025-02-15 08:03
- 2025-02-14 17:14
Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover(Morningstar Research)
- 2025-02-14 13:57
- 2025-02-14 12:10
Bio-Rad set to acquire Stilla Technologies(Medical Device Network)
- 2025-02-14 12:07
Analyst Report: Bio-Rad Laboratories, Inc.(Morningstar Research)
- 2025-02-14 08:46
- 2025-02-14 07:42
- 2025-02-14 07:10
Q4 2024 Bio Rad Laboratories Inc Earnings Call(Thomson Reuters StreetEvents)
- 2025-02-14 05:42
- 2025-02-14 02:22
- 2025-02-13 17:45
- 2025-02-13 16:58
Bio-Rad: Q4 Earnings Snapshot(Associated Press Finance)
- 2025-02-13 16:38
Bio-Rad Laboratories' Q4 Adjusted Earnings, Revenue Fall(MT Newswires)
- 2025-02-13 16:20
- 2025-02-13 16:15
- 2025-02-12 08:37
- 2025-02-12 07:20
- 2025-02-11 08:46
OncoCyte prices $29.1M equity offering(TipRanks)
- 2025-02-10 08:30
Oncocyte Prices $29.1 Million Equity Offering(GlobeNewswire)
- 2025-02-10 07:30
- 2025-02-07 06:50
- 2025-02-07 06:47
- 2025-02-06 10:00
- 2025-02-06 07:21
- 2025-02-04 19:00
BIO: Lowering target price to $279.00(Argus Research)
- 2025-02-04 09:40
- 2025-02-04 06:52
- 2025-01-28 19:00
BIO: Raising target price to $294.00(Argus Research)
Page 1 of 3
previousnext
Disclaimer: The information provided here and on kavout.com is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout makes no recommendations regarding investment decisions based on this information. You are solely responsible for your investments. Please conduct your own research and consult qualified financial advisors before investing. Past performance does not guarantee future results.